Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
Tiziana Life Sciences signed a Memorandum of Understanding with King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases to collaborate on a clinical trial combining its intranasal foralumab with existing anti-CD20 therapy in relapsing-remitting MS patients responding poorly to anti-CD20 alone. The MOU was signed by CEO Ivor Elrifi on the main stage at the Riyadh Global Medical Biotechnology Summit in Saudi Arabia on September 16, 2026. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development, and all 14 na-SPMS patients dosed in the Expanded Access program have shown improvement or stability of disease within 6 months.
Key figures
- Drug Name
- intranasal foralumab
- Phase Of Trial
- Phase 2a
- Ea program nct
- NCT06802328
- Phase2a trial nct
- NCT06292923
- Na spms phase2 readout
- October 2026
- Expanded access patients dosed
- 14
- Prior clinical studies foralumab
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.